Conference Theme: With the Patients, For the Patients: Achieving Health Equity in Primary Care ; Oral Presentation 1.5 ; The Program and Abstract Book can be viewed at: http://www.hkcfp.org.hk/images/stories/documents/HKPCC_2014/HKPCC%202014%20Program%20Book.pdf ; Introduction: Since October 2011, the Hospital Authority (HA) has introduced the Risk Assessment and Management Programme (RAMP) for patients with hypertension (HT) managed in the public primary care setting. The programme aimed to improve cardiovascular outcomes for hypertensive patients through risk assessment, risk stratification and risk-guided management by a multi-disciplinary effort. This study evaluated the clinical benefits of RAMP-HT at 12-month. Method: Evaluation involved 5 clusters under HA that had launched RAMP-HT since Oct 2011. A sampling of 13,155 hypertensive patients aged ≤80, without existing cardiovascular diseases and with suboptimal blood pressure (i.e. systolic blood pressure (SBP) >140mmHg or diastolic blood pressure (DBP) >90mmHg) who were enrolled into RAMP-HT for more than one year was compared to 33,172 non-RAMP-HT participants on clinical outcomes including SBP, low-density lipoprotein cholesterol (LDL-C) and the estimated 10-year cardiovascular disease (CVD) risk using Framingham risk scores equation to reveal the net benefit of RAMP-HT. Multivariate linear regressions were used to identify the net effectiveness of RAMP-HT by adjusting the potential confounding variables. Results: There was a reduction in mean SBP, LDL-C and estimated 10-year cardiovascular risk in both the RAMP-HT participants and hypertensive patients receiving usual care from general-out-patient-clinics (GOPCs) at 12 months. The RAMP-HT participants had greater reduction in LDL-C (coef. = -0.02, P-value = 0.04) and estimated 10-years CVD risk (coef. = -0.45, P-value